# US Lymphedema Diagnostics Market

> US Lymphedema Diagnostics Market Research Report: Size, Share, Trend Analysis By Technology (Lymphoscintigraphy, Magnetic Resonance Imaging, Computed Tomography, Ultrasound Imaging, Others) and By End Users (Hospitals, Diagnostic Centers, Inflammatory Diseases, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.38%
- **2024:** $ 4.8 Million
- **2025:** $ 5.15 Million
- **2035:** $ 10.5 Million
- **Key Players:** LymphaTech (US), Tactile Medical (US), Medi USA (US), BSN Medical (DE), Huntleigh Healthcare (GB), DJO Global (US), Lymphedema Products (US), KCI Medical (US)

**Report ID:** MRFR/MED/16118-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-lymphedema-diagnostics-market-17646

---

## Market Summary

## **US Lymphedema Diagnostics Market Overview**

As per MRFR analysis, the US Lymphedema Diagnostics Market Size was estimated at 4.56 (USD Million) in 2023. The US Lymphedema Diagnostics Market Industry is expected to grow from 5.4(USD Million) in 2024 to 17 (USD Million) by 2035. The US Lymphedema Diagnostics Market CAGR (growth rate) is expected to be around 10.988% during the forecast period (2025 - 2035).

### **Key Market Trends Highlighted**

The US Lymphedema Diagnostics Market is seeing significant growth driven by the increasing prevalence of lymphedema, often linked to rising cases of cancer and obesity, both well-established health concerns in the United States. The aging population is another crucial market driver; as individuals age, the incidence of lymphedema tends to increase. Consequently, the demand for accurate and efficient diagnostic tools is on the rise. Healthcare providers are emphasizing early detection and effective management of lymphedema, leading to advancements in diagnostic technologies and methodologies that enhance patient outcomes.

Opportunities in the US market include the development of at-home diagnostic kits and mobile health applications. These innovations aim to empower patients to monitor their condition while reducing the burden on healthcare facilities. Moreover, partnerships between technology companies and healthcare providers are enabling more cohesive approaches to lymphedema management. The rise of telehealth services also presents an opportunity for remote consultations and follow-ups, making diagnostics more accessible for patients who face mobility challenges or live in remote areas.

Recent trends show a shift toward personalized healthcare in lymphedema diagnostics. This involves tailoring treatment protocols based on individual patient assessments, which can lead to more effective management of the condition. Moreover, there is a growing interest in patient education programs aimed at increasing awareness about lymphedema, promoting early intervention, and ensuring better adherence to treatment plans. The integration of multidisciplinary approaches in treatment is also gaining traction, involving collaboration between specialists to improve overall care for patients with lymphedema.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Lymphedema Diagnostics Market Drivers**

### **Rising Incidence of Cancer Cases**

The increasing prevalence of cancer in the United States is significantly contributing to the growth of the US Lymphedema Diagnostics Market Industry. According to the American Cancer Society, in 2023, an estimated 1.9 million new cancer cases were diagnosed, highlighting the growing population at risk for lymphedema due to cancer treatments such as surgery and radiation. Lymphedema is a common complication following cancer treatment, necessitating proper diagnostics for early intervention.

This rising trend directly increases the demand for advanced diagnostic tools, driving market growth. Furthermore, established organizations like the National Cancer Institute are actively involved in research and dissemination of information related to cancer survivorship, emphasizing the need for standards in lymphedema diagnostics and management. With increasing investments in Research and Development by medical technology companies, the diagnostic solutions tailored for cancer-related lymphedema are expected to expand, benefitting the US Lymphedema Diagnostics Market Industry.

### **Advancements in Diagnostic Technologies**

Innovative technologies in diagnostics such as bioimpedance spectroscopy and advanced imaging techniques are proving to be influential in the US Lymphedema Diagnostics Market Industry. These advancements allow for early detection and more accurate assessment of lymphedema, addressing a significant gap in patient management. The Society of Lymphology reports growing support for these technologies, encouraging their adoption in clinical practice.

Furthermore, well-established medical device companies are pursuing patents for novel diagnostic tools, signifying continued product development in this sector. As hospitals and clinics adopt these advanced technologies, increased efficiency, and accuracy in diagnosis will likely enhance patient outcomes and drive market expansion.

### **Increasing Awareness and Education on Lymphedema**

The heightened focus on the education and awareness surrounding lymphedema is emerging as a vital driver for the US Lymphedema Diagnostics Market Industry. Advocacy groups such as the Lymphatic Education & Research Network are instrumental in raising awareness among both healthcare professionals and patients about the importance of early detection and treatment of lymphedema. Recent initiatives have shown a 30% increase in attendance at workshops and seminars dedicated to lymphedema management, illustrating a growing interest in this area.

As awareness increases, both patients and healthcare providers are more likely to seek diagnostic tests and interventions, driving demand in the marketplace. Public health campaigns will further assist in normalizing lymphedema screening, ensuring that diagnostic market growth aligns with these educational efforts.

## **US Lymphedema Diagnostics Market Segment Insights**

### **Lymphedema Diagnostics Market Technology Insights**

The US **[Lymphedema Diagnostics Market](../../../reports/lymphedema-diagnostics-market-8761)**within the Technology segment is experiencing notable advancements, particularly due to the increasing prevalence of lymphedema among the population, which is projected to rise significantly. The importance of effective diagnostic tools cannot be understated, as they play a critical role in the timely detection and management of lymphedema. Within this segment, Lymphoscintigraphy is recognized for its ability to visualize lymphatic pathways and identify blockages, becoming a preferred diagnostic method due to its precision and reliability.

Magnetic Resonance Imaging has gained traction for its non-invasive capabilities and its high-resolution images, allowing for detailed soft tissue evaluation, which is essential for accurate diagnosis. Computed Tomography offers the advantage of rapid imaging and a comprehensive view of the abdomen and pelvis, which is vital for assessing potential lymphedema causes. Meanwhile, Ultrasound Imaging is increasingly used for its accessibility and cost-effectiveness, as it provides clinicians with immediate results while being safe for longitudinal studies.

Several other innovative technologies, categorized under 'Others,' are also emerging, focusing on personalized diagnostics and treatment pathways, thus enhancing patient outcomes. The US government and health organizations have highlighted the necessity for cutting-edge technology in healthcare, reflecting a robust push towards integrating advanced diagnostics to improve patient management strategies significantly. Furthermore, trends in the market indicate strong investment in Research and Development driven by the need for more effective diagnostic methods and the continuous evolution of imaging technologies.

As the market evolves, these diagnostic technologies are poised to reshape the landscape of lymphedema diagnosis, presenting comprehensive solutions aimed at improving quality of life for affected individuals. Overall, the Technology segment is anticipated to witness substantial growth, propelled by ongoing innovations and an increased focus on patient-centric care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Lymphedema Diagnostics Market End User Insights**

The US Lymphedema Diagnostics Market focused on the End User segment is witnessing significant growth driven by the increasing prevalence of lymphedema and related inflammatory diseases across the country. Hospitals emerge as major players due to their comprehensive facilities that enable accurate diagnosis and management of lymphedema, appealing to a wide patient demographic. Diagnostic centers play a vital role by providing specialized equipment and tailored services, enabling quicker diagnosis which is essential for effective treatment strategies.

Inflammatory diseases significantly contribute to the demand for lymphedema diagnostics, as conditions such as cancer and obesity lead to higher incidences of lymphedema, thus driving the need for advanced diagnostic solutions. The 'Others' category, which may encompass outpatient clinics and rehabilitation centers, also showcases an increasing importance in providing patient-centered care and expanding access to early diagnosis and treatment interventions. This diversification of End Users highlights a broader acceptance of lymphedema care and the rising awareness regarding the diagnosis, ultimately improving patient outcomes.

Overall, the dynamics of the US Lymphedema Diagnostics Market are characterized by a growing emphasis on early detection and appropriate management across various health service dimensions.

## **US Lymphedema Diagnostics Market Key Players and Competitive Insights**

The US Lymphedema Diagnostics Market is characterized by a competitive landscape that is continuously evolving, driven by a growing awareness of lymphedema and the need for effective diagnostic tools. This market is marked by the involvement of various key players who are focused on enhancing their product offerings, improving technological advancements, and expanding their market reach through strategic partnerships and collaborations. The competition is shaped by the increasing prevalence of lymphedema, owing to factors such as cancer treatments, surgical procedures, and genetic disorders that lead to the risk of developing this condition.

As healthcare continues to prioritize patient solutions, distinguishing features such as innovation, regulatory compliance, and the capability to provide comprehensive management solutions are critical for players in this space. In the context of the US Lymphedema Diagnostics Market, Dynatronics possesses a strong presence anchored primarily by its innovative approach to product development and expandability of its portfolio. The company focuses on the manufacturing and distribution of therapeutic devices that assist in the diagnosis and management of lymphedema.

By leveraging its established relationships with healthcare providers and its commitment to quality and patient care, Dynatronics maintains a competitive edge in providing tailored solutions that meet the demands of clinicians and patients. The company’s emphasis on advancing technology in lymphedema diagnostics sets it apart from competitors, thereby solidifying its role as a competent player in the market.

BSN Medical also plays a significant role in the US Lymphedema Diagnostics Market, recognized for offering a wide array of products geared towards the management and treatment of lymphedema. The company's key offerings include compression therapy solutions and diagnostic tools, enabling clinicians to adopt effective treatment regimens. BSN Medical’s robust market presence is fortified through strategic mergers and acquisitions that have expanded its product line and distribution network. This company emphasizes innovation in its service delivery and product development, ensuring that it meets evolving medical needs.

Additionally, BSN Medical's emphasis on high-quality standards and customer service reinforces its reputation as a trusted provider in lymphedema diagnostics, making it a prominent force in the US market landscape.

## **Key Companies in the US Lymphedema Diagnostics Market Include**

## **US Lymphedema Diagnostics Market Industry Developments**

Recent developments in the US Lymphedema Diagnostics Market have highlighted growth potential and emerging technologies in lymphedema management. Companies like Dynatronics, BSN Medical, and Tactile Medical have been actively involved in the introduction of innovative diagnostic devices and treatment modalities aimed at improving patient outcomes. For instance, in September 2023, Tactile Medical expanded its product offerings to include advanced lymphedema treatment solutions, reinforcing its market position.

Current affairs indicate a growing emphasis on collaboration and partnerships among key players. Arjo and Cardinal Health announced a strategic alliance in October 2023 to enhance their product reach in the lymphedema diagnostics landscape. Additionally, the market has witnessed notable merger activities; in April 2023, KCI Medical was acquired by 3M, integrating its lymphedema management solutions into 3M’s broader health product portfolio, impacting market valuations positively.

The US healthcare system's push for improved patient management in chronic conditions has led to increased funding in lymphedema research, further accelerated by federal initiatives promoting early diagnosis and treatment. Overall, the US Lymphedema Diagnostics Market is becoming increasingly dynamic, with significant advancements and strategic maneuvers shaping its future landscape.

## **US Lymphedema Diagnostics Market Segmentation Insights**

### **Lymphedema Diagnostics Market Technology Outlook**

### **Lymphedema Diagnostics Market End User Outlook**

## Market Drivers

### Growing Healthcare Expenditure

The rising healthcare expenditure in the US is a significant driver for the lymphedema diagnostics market. With healthcare spending projected to reach approximately $6 trillion by 2027, there is a growing emphasis on early diagnosis and management of chronic conditions, including lymphedema. Increased funding for healthcare services allows for the procurement of advanced diagnostic equipment and technologies. This trend is likely to enhance the availability of lymphedema diagnostic services across various healthcare settings, including hospitals and outpatient clinics. As healthcare providers invest in better diagnostic capabilities, the market is expected to expand, catering to the needs of a larger patient population.

### Rising Incidence of Lymphedema

The increasing incidence of lymphedema in the US is a primary driver for this market. Factors such as an aging population and the prevalence of conditions like cancer and obesity contribute to this rise. According to recent estimates, approximately 3-5 million individuals in the US are affected by lymphedema, which underscores the need for effective diagnostic solutions. As awareness of the condition grows, healthcare providers are more likely to seek advanced diagnostic tools to identify and manage lymphedema early. This trend is expected to propel the market forward, as more patients seek diagnosis and treatment options, thereby increasing demand for innovative diagnostic technologies.

### Supportive Government Initiatives

Supportive government initiatives aimed at improving healthcare access and quality are positively impacting the lymphedema diagnostics market. Programs that promote early detection and management of chronic diseases, including lymphedema, are gaining traction. Federal and state funding for research and development in diagnostic technologies is also on the rise, which may lead to the introduction of innovative solutions in the market. Additionally, public health campaigns aimed at raising awareness about lymphedema are likely to encourage more individuals to seek diagnostic services. As these initiatives continue to evolve, they are expected to create a favorable environment for the growth of the lymphedema diagnostics market.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are significantly influencing the lymphedema diagnostics market. Innovations such as bioimpedance spectroscopy, near-infrared imaging, and advanced ultrasound techniques are enhancing the accuracy and efficiency of lymphedema diagnosis. These technologies allow for non-invasive assessments, which are increasingly preferred by both patients and healthcare providers. The market is projected to grow as these advanced diagnostic solutions become more widely adopted. Furthermore, the integration of artificial intelligence in diagnostic processes may streamline workflows and improve patient outcomes, thereby driving market growth. As healthcare systems prioritize precision medicine, the demand for sophisticated diagnostic tools is likely to increase.

### Increased Focus on Patient-Centric Care

The shift towards patient-centric care in the US healthcare system is driving the lymphedema diagnostics market. This approach emphasizes personalized treatment plans and improved patient engagement, which necessitates accurate and timely diagnostics. Healthcare providers are increasingly recognizing the importance of involving patients in their care decisions, leading to a demand for diagnostic tools that provide clear and actionable insights. As patients become more informed about their health conditions, they are likely to seek out diagnostic services that align with their preferences. This trend is expected to foster growth in the lymphedema diagnostics market, as providers adapt to meet the evolving expectations of patients.

## Future Outlook

The [Lymphedema Diagnostics Market](https://www.marketresearchfuture.com/reports/lymphedema-diagnostics-market-8761) is projected to grow at a 7.38% CAGR from 2025 to 2035, driven by technological advancements, increasing awareness, and rising prevalence of lymphedema.

**New opportunities:**

- Development of AI-driven diagnostic tools for early detection. Expansion of telehealth services for remote patient monitoring. Partnerships with healthcare providers for integrated care solutions.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced diagnostic capabilities and patient access.

## Segment Insights

### By Type: Lymphoscintigraphy (Largest) vs. Ultrasound Imaging (Fastest-Growing)

In the US lymphedema diagnostics market, Lymphoscintigraphy holds the largest market share among diagnostic types due to its effectiveness in identifying lymphatic flow and functionality. Its established reputation in clinical settings ensures consistent demand, particularly for assessing lymphatic issues. In contrast, Ultrasound Imaging is gaining traction as the fastest-growing segment, thanks to advancements in technology that enhance its diagnostic capabilities and patient comfort, positioning it rapidly within the market.

The growth trends for these segment values are influenced by increasing awareness of lymphedema conditions and the rising prevalence of related disorders. Innovations in imaging technologies, coupled with supportive healthcare policies, further facilitate the adoption of devices like Ultrasound Imaging, which offers non-invasive methods. As patients and clinicians seek more reliable and comfortable diagnostic options, the demand for these technologies is expected to grow significantly, shaping the lymphedema diagnostics landscape in the coming years.

Lymphoscintigraphy (Dominant) vs. Ultrasound Imaging (Emerging)

Lymphoscintigraphy is recognized as the dominant technique in lymphedema diagnostics due to its comprehensive ability to visualize lymphatic circulation and its effectiveness in clinical diagnosis. Its long-established use in hospitals and clinics provides physicians confidence in its results, making it the preferred choice for detailed assessments. Conversely, Ultrasound Imaging is an emerging technique that offers several advantages, including quicker procedures and enhanced patient experiences. The ease of use and immediate results from Ultrasound Imaging are attractive to healthcare providers, contributing to its rapid adoption and growth as more practitioners recognize its potential in early detection and management of lymphedema.

### By End User: Hospitals (Largest) vs. Diagnostic Centers (Fastest-Growing)

In the US lymphedema diagnostics market, hospitals account for a significant portion of the overall market share due to their comprehensive service offerings and resources dedicated to specialized care. This segment remains dominant, leveraging advanced technology and highly trained personnel to manage complex lymphedema cases. Conversely, diagnostic centers represent the fastest-growing segment, driven by an increase in specialized diagnostic services and early detection initiatives, attracting a broader patient base.

The growth trends indicate a shift towards outpatient care, with diagnostic centers emerging at the forefront. As awareness of lymphedema increases among healthcare providers and patients, demand for diagnostic services is expected to rise. Factors such as technological advancements in diagnostic tools and an increase in lifestyle-related conditions are fueling this growth, positioning diagnostic centers as pivotal players in the market's evolution.

Hospitals (Dominant) vs. Diagnostic Centers (Emerging)

Hospitals play a dominant role in the US lymphedema diagnostics market, primarily due to their extensive capabilities in providing comprehensive care, including diagnostics, treatment, and rehabilitation. They typically possess advanced diagnostic equipment and a multidisciplinary approach to patient management. In contrast, diagnostic centers are considered emerging players, focusing on specialized lymphedema evaluation and early intervention. These centers utilize cutting-edge technology and personalized care strategies, appealing to patients seeking quicker access to diagnosis and treatment. As healthcare shifts towards more targeted and efficient care, both hospitals and diagnostic centers are essential for effective lymphedema management, each addressing distinct yet complementary aspects of patient needs.

## Competitive Benchmarking

The lymphedema diagnostics market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as LymphaTech (US), Tactile Medical (US), and DJO Global (US) are actively pursuing strategies that emphasize technological advancements and enhanced service delivery. LymphaTech (US) has positioned itself as a leader in developing advanced diagnostic tools, focusing on integrating digital technologies to improve patient outcomes. Tactile Medical (US) has adopted a strategy centered on expanding its product portfolio and enhancing accessibility through partnerships with healthcare providers, thereby increasing its market penetration. DJO Global (US) is leveraging its extensive distribution network to optimize supply chain efficiencies, which is crucial in a market that demands timely and effective solutions for lymphedema management.The business tactics employed by these companies reflect a moderately fragmented market structure, where localized manufacturing and supply chain optimization are pivotal. The collective influence of these key players is significant, as they not only drive innovation but also set benchmarks for quality and service standards within the market. This competitive environment encourages ongoing investment in research and development, which is essential for maintaining relevance in a rapidly evolving healthcare landscape.
In October Tactile Medical (US) announced a strategic partnership with a leading telehealth provider to enhance remote patient monitoring capabilities. This move is indicative of a broader trend towards digital health solutions, allowing for more efficient patient management and potentially improving adherence to treatment protocols. The integration of telehealth services is likely to expand Tactile Medical's reach and improve patient engagement, which is critical in managing chronic conditions like lymphedema.
In September LymphaTech (US) launched a new diagnostic device that utilizes AI algorithms to enhance the accuracy of lymphedema detection. This innovation not only positions LymphaTech at the forefront of technological advancement but also addresses the growing demand for precise diagnostic tools in the healthcare sector. The incorporation of AI into diagnostics could significantly reduce the time to diagnosis, thereby improving patient outcomes and streamlining treatment pathways.
In August DJO Global (US) expanded its product line to include a new range of compression garments designed specifically for lymphedema patients. This expansion reflects DJO's commitment to providing comprehensive solutions that cater to the diverse needs of patients. By diversifying its offerings, DJO Global enhances its competitive edge and addresses the multifaceted challenges faced by lymphedema patients.
As of November the competitive trends within the lymphedema diagnostics market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing service delivery and expanding market reach. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation and technological advancements rather than solely on price. The emphasis on reliable supply chains and cutting-edge solutions is likely to shape the future landscape of the market, fostering an environment where patient outcomes are prioritized.

## Recent News & Developments

Recent developments in the US Lymphedema Diagnostics Market have highlighted growth potential and emerging technologies in lymphedema management. Companies like Dynatronics, BSN Medical, and Tactile Medical have been actively involved in the introduction of innovative diagnostic devices and treatment modalities aimed at improving patient outcomes. For instance, in September 2023, Tactile Medical expanded its product offerings to include advanced lymphedema treatment solutions, reinforcing its market position.

Current affairs indicate a growing emphasis on collaboration and partnerships among key players. Arjo and Cardinal Health announced a strategic alliance in October 2023 to enhance their product reach in the lymphedema diagnostics landscape. Additionally, the market has witnessed notable merger activities; in April 2023, KCI Medical was acquired by 3M, integrating its lymphedema management solutions into 3M’s broader health product portfolio, impacting market valuations positively.

The US healthcare system's push for improved patient management in chronic conditions has led to increased funding in lymphedema research, further accelerated by federal initiatives promoting early diagnosis and treatment. Overall, the US Lymphedema Diagnostics Market is becoming increasingly dynamic, with significant advancements and strategic maneuvers shaping its future landscape.

## Report Scope

| MARKET SIZE 2024 | 4.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 5.15(USD Million) |
| MARKET SIZE 2035 | 10.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.38% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | LymphaTech (US), Tactile Medical (US), Medi USA (US), BSN Medical (DE), Huntleigh Healthcare (GB), DJO Global (US), Lymphedema Products (US), KCI Medical (US) |
| Segments Covered | Type, End User |
| Key Market Opportunities | Integration of advanced imaging technologies enhances early detection in the lymphedema diagnostics market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in lymphedema diagnostics, enhancing patient outcomes and market growth. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US lymphedema diagnostics market in 2024?**
A: The overall market valuation was $4.8 Million in 2024.

**Q: What is the projected market valuation for the US lymphedema diagnostics market by 2035?**
A: The projected valuation for 2035 is $10.5 Million.

**Q: What is the expected CAGR for the US lymphedema diagnostics market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.38%.

**Q: Which companies are considered key players in the US lymphedema diagnostics market?**
A: Key players include LymphaTech, Tactile Medical, Medi USA, BSN Medical, Huntleigh Healthcare, DJO Global, Lymphedema Products, and KCI Medical.

**Q: What segment had the highest valuation in the US lymphedema diagnostics market in 2024?**
A: In 2024, the segment with the highest valuation was Lymphoscintigraphy, valued at $0.8 Million.

**Q: How much is the Magnetic Resonance Imaging segment projected to grow by 2035?**
A: The Magnetic Resonance Imaging segment is projected to grow from $1.2 Million in 2024 to $2.5 Million by 2035.

**Q: What is the projected valuation for the Ultrasound Imaging segment by 2035?**
A: The Ultrasound Imaging segment is projected to reach $2.2 Million by 2035.

**Q: Which end user segment is expected to show significant growth in the US lymphedema diagnostics market?**
A: The Hospitals segment is expected to show significant growth, increasing from $1.5 Million in 2024 to $3.2 Million by 2035.

**Q: What is the projected growth for Diagnostic Centers in the US lymphedema diagnostics market?**
A: The Diagnostic Centers segment is projected to grow from $1.2 Million in 2024 to $2.5 Million by 2035.

**Q: What does the future hold for the Others segment in the Type category by 2035?**
A: The Others segment in the Type category is expected to grow from $0.8 Million in 2024 to $1.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-lymphedema-diagnostics-market-17646*